{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000046","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.207789+00:00","generated_at":"2026-05-19T04:29:17.485589+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen reports FY2025 net loss $51.4M; cash $80.5M; advances PALISADE fasedienol trials","bullets":["FY2025 net loss $51.4M (vs $29.4M prior year); R&D expenses doubled to $39.4M on fasedienol and PH80 programs.","Cash, cash equivalents and marketable securities $80.5M as of March 31, 2025.","PALISADE-3 fasedienol topline results expected Q4 2025; PALISADE-4 results expected H1 2026.","Filed prospectus supplement to sell up to $175M common stock via ATM (replacing $100M prior); ~$3.4M already sold.","Itruvone for MDD planning further Phase 2; PH80 for menopausal hot flashes preparing U.S. IND."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000046","json":"https://secwatch.observer/filing/0001411685-25-000046.json","markdown":"https://secwatch.observer/filing/0001411685-25-000046.md","text":"https://secwatch.observer/filing/0001411685-25-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000046/0001411685-25-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000046/vtgn-20250617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:29:17.485589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}